Literature DB >> 28123895

The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis.

Silvio Bandini1, Marco Macagno1, Albana Hysi2, Stefania Lanzardo1, Laura Conti1, Amanda Bello1, Federica Riccardo1, Roberto Ruiu1, Irene Fiore Merighi1, Guido Forni1, Manuela Iezzi2, Elena Quaglino1, Federica Cavallo1.   

Abstract

There is an ever increasing amount of evidence to support the hypothesis that complement C1q, the first component of the classical complement pathway, is involved in the regulation of cancer growth, in addition to its role in fighting infections. It has been demonstrated that C1q is expressed in the microenvironment of various types of human tumors, including breast adenocarcinomas. This study compares carcinogenesis progression in C1q deficient (neuT-C1KO) and C1q competent neuT mice in order to investigate the role of C1q in mammary carcinogenesis. Significantly accelerated autochthonous neu+ carcinoma progression was paralleled by accelerated spontaneous lung metastases occurrence in C1q deficient mice. Surprisingly, this effect was not caused by differences in the tumor-infiltrating cells or in the activation of the complement classical pathway, since neuT-C1KO mice did not display a reduction in C3 fragment deposition at the tumor site. By contrast, a significant higher number of intratumor blood vessels and a decrease in the activation of the tumor suppressor WW domain containing oxidoreductase (WWOX) were observed in tumors from neuT-C1KO as compare with neuT mice. In parallel, an increase in Her2/neu expression was observed on the membrane of tumor cells. Taken together, our findings suggest that C1q plays a direct role both on halting tumor angiogenesis and on inducing apoptosis in mammary cancer cells by coordinating the signal transduction pathways linked to WWOX and, furthermore, highlight the role of C1q in mammary tumor immune surveillance regardless of complement system activation.

Entities:  

Keywords:  C1q; Complement; ErbB2; Her2/neu; genetically engineered mice; immunosurveillance; mammary cancer

Year:  2016        PMID: 28123895      PMCID: PMC5214935          DOI: 10.1080/2162402X.2016.1253653

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  50 in total

Review 1.  Structural and functional anatomy of the globular domain of complement protein C1q.

Authors:  Uday Kishore; Rohit Ghai; Trevor J Greenhough; Annette K Shrive; Domenico M Bonifati; Mihaela G Gadjeva; Patrick Waters; Mihaela S Kojouharova; Trinad Chakraborty; Alok Agrawal
Journal:  Immunol Lett       Date:  2004-09       Impact factor: 3.685

Review 2.  The complement system: an unexpected role in synaptic pruning during development and disease.

Authors:  Alexander H Stephan; Ben A Barres; Beth Stevens
Journal:  Annu Rev Neurosci       Date:  2012       Impact factor: 12.449

3.  HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.

Authors:  Riki Okita; Dimitrios Mougiakakos; Takashi Ando; Yumeng Mao; Dhifaf Sarhan; Erik Wennerberg; Barbara Seliger; Andreas Lundqvist; Kousaku Mimura; Rolf Kiessling
Journal:  J Immunol       Date:  2012-02-01       Impact factor: 5.422

4.  Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.

Authors:  Annalisa Astolfi; Lorena Landuzzi; Giordano Nicoletti; Carla De Giovanni; Stefania Croci; Arianna Palladini; Silvano Ferrini; Manuela Iezzi; Piero Musiani; Federica Cavallo; Guido Forni; Patrizia Nanni; Pier-Luigi Lollini
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

5.  Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition.

Authors:  Min Soon Cho; Rajesha Rupaimoole; Hyun-Jin Choi; Kyunghee Noh; Jichao Chen; Qianghua Hu; Anil K Sood; Vahid Afshar-Kharghan
Journal:  J Immunol       Date:  2015-12-30       Impact factor: 5.422

6.  Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice.

Authors:  Marco Macagno; Silvio Bandini; Lorenzo Stramucci; Elena Quaglino; Laura Conti; Elisa Balmas; Mark J Smyth; Pier-Luigi Lollini; Piero Musiani; Guido Forni; Manuela Iezzi; Federica Cavallo
Journal:  J Immunol       Date:  2014-04-30       Impact factor: 5.422

Review 7.  ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas.

Authors:  Elena Quaglino; Cristina Mastini; Guido Forni; Federica Cavallo
Journal:  Curr Protoc Immunol       Date:  2008-08

8.  Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression.

Authors:  Masayuki Inoue; Kousaku Mimura; Shinichiro Izawa; Kensuke Shiraishi; Ayako Inoue; Shugo Shiba; Mitsuaki Watanabe; Takanori Maruyama; Yoshihiko Kawaguchi; Shingo Inoue; Tomonori Kawasaki; Aniruddha Choudhury; Ryohei Katoh; Hideki Fujii; Rolf Kiessling; Koji Kono
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

9.  The human c1q globular domain: structure and recognition of non-immune self ligands.

Authors:  Christine Gaboriaud; Philippe Frachet; Nicole M Thielens; Gérard J Arlaud
Journal:  Front Immunol       Date:  2012-01-06       Impact factor: 7.561

10.  Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells.

Authors:  Qunying Hong; Chun-I Sze; Sing-Ru Lin; Ming-Hui Lee; Ruei-Yu He; Lori Schultz; Jean-Yun Chang; Shean-Jen Chen; Robert J Boackle; Li-Jin Hsu; Nan-Shan Chang
Journal:  PLoS One       Date:  2009-06-01       Impact factor: 3.240

View more
  17 in total

Review 1.  Phosphorylation/de-phosphorylation in specific sites of tumor suppressor WWOX and control of distinct biological events.

Authors:  Shenq-Shyang Huang; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-08

2.  Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells.

Authors:  Gaetano Donofrio; Giulia Tebaldi; Stefania Lanzardo; Roberto Ruiu; Elisabetta Bolli; Andrea Ballatore; Valeria Rolih; Francesca Macchi; Laura Conti; Federica Cavallo
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110

Review 3.  C1q: A fresh look upon an old molecule.

Authors:  Nicole M Thielens; Francesco Tedesco; Suzanne S Bohlson; Christine Gaboriaud; Andrea J Tenner
Journal:  Mol Immunol       Date:  2017-06-07       Impact factor: 4.407

4.  Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy.

Authors:  Antonino Di Lorenzo; Elisabetta Bolli; Roberto Ruiu; Giuseppe Ferrauto; Enza Di Gregorio; Lidia Avalle; Aurora Savino; Pietro Poggio; Irene Fiore Merighi; Federica Riccardo; Mara Brancaccio; Elena Quaglino; Federica Cavallo; Laura Conti
Journal:  Oncoimmunology       Date:  2022-06-15       Impact factor: 7.723

5.  Is the Complement Protein C1q a Pro- or Anti-tumorigenic Factor? Bioinformatics Analysis Involving Human Carcinomas.

Authors:  Alessandro Mangogna; Chiara Agostinis; Deborah Bonazza; Beatrice Belmonte; Paola Zacchi; Gabriella Zito; Andrea Romano; Fabrizio Zanconati; Giuseppe Ricci; Uday Kishore; Roberta Bulla
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

6.  Prognostic Implications of the Complement Protein C1q in Gliomas.

Authors:  Alessandro Mangogna; Beatrice Belmonte; Chiara Agostinis; Paola Zacchi; Domenico Gerardo Iacopino; Anna Martorana; Vito Rodolico; Deborah Bonazza; Fabrizio Zanconati; Uday Kishore; Roberta Bulla
Journal:  Front Immunol       Date:  2019-10-10       Impact factor: 7.561

7.  Prognostic Implications of the Complement Protein C1Q and Its Correlation with Immune Infiltrates in Osteosarcoma.

Authors:  Hanji Huang; Manli Tan; Li Zheng; Guohua Yan; Kanglu Li; Dejie Lu; Xiaofei Cui; Si He; Danqing Lei; Bo Zhu; Jinmin Zhao
Journal:  Onco Targets Ther       Date:  2021-03-05       Impact factor: 4.147

Review 8.  Context-dependent roles of complement in cancer.

Authors:  Lubka T Roumenina; Marie V Daugan; Florent Petitprez; Catherine Sautès-Fridman; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

9.  Low expression of WW domain-containing oxidoreductase associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection.

Authors:  Chenhao Zhou; Wanyong Chen; Jialei Sun; Manar Atyah; Yirui Yin; Wentao Zhang; Lei Guo; Qinghai Ye; Qiongzhu Dong; Yi Shi; Ning Ren
Journal:  Cancer Med       Date:  2018-06-14       Impact factor: 4.452

Review 10.  Role of the complement system in the tumor microenvironment.

Authors:  Ronghua Zhang; Qiaofei Liu; Tong Li; Quan Liao; Yupei Zhao
Journal:  Cancer Cell Int       Date:  2019-11-15       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.